A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
Latest Information Update: 11 May 2021
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Rhythm
Most Recent Events
- 06 May 2021 Status changed from recruiting to completed.
- 30 Dec 2020 Planned End Date changed from 12 Jan 2021 to 10 Mar 2021.
- 30 Dec 2020 Planned primary completion date changed from 14 Dec 2020 to 10 Mar 2021.